103 related articles for article (PubMed ID: 34355430)
1. Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10 839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015.
Nakai Y; Tanaka N; Fujii T; Miyake M; Anai S; Hori S; Shimizu T; Onishi M; Ichikawa K; Onishi K; Fujimoto K
Int J Urol; 2021 Nov; 28(11):1164-1170. PubMed ID: 34355430
[TBL] [Abstract][Full Text] [Related]
2. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data.
Tanaka N; Fujimoto K; Hirayama A; Yoneda T; Yoshida K; Hirao Y
Jpn J Clin Oncol; 2010 Jun; 40(6):588-92. PubMed ID: 20299498
[TBL] [Abstract][Full Text] [Related]
3. Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012.
Tanaka N; Nakai Y; Miyake M; Anai S; Inoue T; Fujii T; Konishi N; Fujimoto K
BMC Cancer; 2017 Sep; 17(1):616. PubMed ID: 28865421
[TBL] [Abstract][Full Text] [Related]
4. Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)--a comparison between 2004-2006 and 2007-2009.
Tanaka N; Hirayama A; Yoneda T; Yoshida K; Shimada K; Konishi N; Fujimoto K
BMC Cancer; 2013 Dec; 13():588. PubMed ID: 24325407
[TBL] [Abstract][Full Text] [Related]
5. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan.
Onozawa M; Hinotsu S; Tsukamoto T; Oya M; Ogawa O; Kitamura T; Suzuki K; Naito S; Namiki M; Nishimura K; Hirao Y; Akaza H
Jpn J Clin Oncol; 2014 Oct; 44(10):969-81. PubMed ID: 25098707
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy or watchful waiting in early prostate cancer.
Bill-Axelson A; Holmberg L; Garmo H; Rider JR; Taari K; Busch C; Nordling S; Häggman M; Andersson SO; Spångberg A; Andrén O; Palmgren J; Steineck G; Adami HO; Johansson JE
N Engl J Med; 2014 Mar; 370(10):932-42. PubMed ID: 24597866
[TBL] [Abstract][Full Text] [Related]
8. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
[TBL] [Abstract][Full Text] [Related]
9. Trends in primary treatment for localized prostate cancer according to the availability of treatment modalities and the impact of introducing robotic surgery.
Hori S; Nakai Y; Tomizawa M; Morizawa Y; Gotoh D; Miyake M; Anai S; Torimoto K; Yoneda T; Fujimoto K; Tanaka N
Int J Urol; 2022 Nov; 29(11):1371-1379. PubMed ID: 35976679
[TBL] [Abstract][Full Text] [Related]
10. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR;
J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425
[TBL] [Abstract][Full Text] [Related]
11. [CLINICAL SURVEILLANCE OF PROSTATE CANCER--COMPARISON WITH CLINICAL MASS STUDY IN JAPAN].
Takada T; Minato N; Koga M; Sugao H
Nihon Hinyokika Gakkai Zasshi; 2015 Apr; 106(2):79-88. PubMed ID: 26415357
[TBL] [Abstract][Full Text] [Related]
12. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
13. Interdisciplinary decision making in prostate cancer therapy - 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin.
Baumunk D; Reunkoff R; Kushner J; Baumunk A; Kempkensteffen C; Steiner U; Weikert S; Moser L; Schrader M; Höcht S; Wiegel T; Miller K; Schostak M
BMC Med Inform Decis Mak; 2013 Aug; 13():83. PubMed ID: 23915212
[TBL] [Abstract][Full Text] [Related]
14. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry.
Weerakoon M; Papa N; Lawrentschuk N; Evans S; Millar J; Frydenberg M; Bolton D; Murphy DG
BJU Int; 2015 Apr; 115 Suppl 5():50-6. PubMed ID: 25601201
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
Meng MV; Elkin EP; Latini DM; Duchane J; Carroll PR
J Urol; 2005 May; 173(5):1557-61. PubMed ID: 15821485
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
17. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
18. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
[TBL] [Abstract][Full Text] [Related]
19. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
[TBL] [Abstract][Full Text] [Related]
20. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
Cooperberg MR; Vickers AJ; Broering JM; Carroll PR
Cancer; 2010 Nov; 116(22):5226-34. PubMed ID: 20690197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
